Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies
Juan Manuel Carreño, Gagandeep Singh, Viviana Simon, Florian Krammer
Abstract
Vaccination against COVID-19 increased immunity in the population, which reduced viral transmission and protected against severe disease. However, continuous emergence of SARS-CoV-2 variants required the implementation of bivalent boosters including the wild-type (D614G) and omicron (BA.5) spike. Improved effectiveness of the bivalent booster versus monovalent booster against omicron subvariants has been reported;1 however, few differences in the immune response have been detected.2,3
Topics & Concepts
Bivalent (engine)AntibodyBooster doseVirologyPopulationMedicineChemistryImmunologyTiterMetalEnvironmental healthOrganic chemistrySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesAnimal Virus Infections Studies